Vivani Medical's (VANI) Buy Rating Reiterated at HC Wainwright

Vivani Medical (NASDAQ:VANI - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright's price target indicates a potential upside of 253.98% from the stock's previous close. HC Wainwright also issued estimates for Vivani Medical's Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.33) EPS.

Vivani Medical Stock Down 0.9%

Shares of NASDAQ VANI traded down $0.01 during midday trading on Monday, hitting $1.13. The stock had a trading volume of 22,655 shares, compared to its average volume of 162,459. The business's 50 day moving average is $1.05 and its 200-day moving average is $1.16. The company has a market cap of $66.95 million, a P/E ratio of -2.51 and a beta of 2.81. Vivani Medical has a 52 week low of $0.91 and a 52 week high of $2.09.

Vivani Medical (NASDAQ:VANI - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, analysts expect that Vivani Medical will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Vivani Medical

In other news, Director Gregg Williams acquired 34,000 shares of Vivani Medical stock in a transaction dated Friday, April 4th. The stock was purchased at an average cost of $0.99 per share, with a total value of $33,660.00. Following the completion of the purchase, the director now directly owns 4,754,800 shares in the company, valued at approximately $4,707,252. This trade represents a 0.72% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders acquired 121,662 shares of company stock valued at $121,636. Insiders own 46.40% of the company's stock.

Institutional Trading of Vivani Medical

Hedge funds and other institutional investors have recently modified their holdings of the company. Connective Capital Management LLC boosted its position in shares of Vivani Medical by 796.2% during the first quarter. Connective Capital Management LLC now owns 162,098 shares of the company's stock worth $170,000 after acquiring an additional 144,010 shares during the last quarter. Wealthedge Investment Advisors LLC lifted its holdings in shares of Vivani Medical by 238.8% in the 1st quarter. Wealthedge Investment Advisors LLC now owns 125,033 shares of the company's stock worth $131,000 after acquiring an additional 88,132 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Vivani Medical in the 4th quarter worth about $66,000. Finally, Northern Trust Corp lifted its holdings in shares of Vivani Medical by 19.1% in the 4th quarter. Northern Trust Corp now owns 71,915 shares of the company's stock worth $83,000 after acquiring an additional 11,540 shares during the last quarter. 6.78% of the stock is owned by hedge funds and other institutional investors.

Vivani Medical Company Profile

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.